Artelo Biosciences (ARTL) said Monday that new preclinical data showed its drug candidate ART12.11 demonstrated antidepressant-like activity and cognitive benefits in a stress-induced depression model in rats.
The company said a 28-day regimen reversed depressive behaviors and improved cognitive function, performing comparably to the selective serotonin reuptake inhibitor Sertraline in behavioral measures.
ART12.11 also restored spatial and short-term memory deficits without negatively impacting social memory, according to the company.
The company's shares were up 179% in recent premarket activity on Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。